Allergan Plans To Launch Ophthalmic Antihistamine Elestat In First Quarter
Allergan expects to launch the ophthalmic antihistamine Elestat (epinastine) during the first quarter of 2004
You may also be interested in...
Allergan could enter the retinal therapy market in late 2006 with Oculex' macular edema implant Posurdex following its $230 mil. acquisition of the technology company
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials